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ABSTRACT
Introduction: Previous studies have
demonstrated the superior efficacy of a novel
aerosol foam formulation of fixed combination
calcipotriene 0.005% (Cal) and betamethasone
dipropionate 0.064% (BD), compared with the
ointment formulation. The aim of this study is
to ascertain whether enhanced bioavailability
of the active ingredients due to supersaturation
and/or occlusive properties can explain the
observed greater clinical efficacy.
Methods: Solubility and evaporation
experiments were conducted to examine the
abilities of Cal/BD aerosol foam ingredients to
create a supersaturated environment. Optical
microscopy, Raman imaging and X-ray powder
diffraction were used to examine the physical
state of Cal and BD in the formulations after
application, and determine whether a
supersaturated state remained stable for
clinically relevant time periods. In vitro skin
penetration and ex vivo biomarker assays were
conducted to compare the skin penetration and
bioavailability of Cal and BD from the aerosol
foam and ointment formulations, respectively.
Occlusive properties were examined via
transepidermal water loss.
Results: Solubility studies showed that Cal and
BD solubility increased with increasing
dimethyl ether (DME) content. Both active
ingredients are completely dissolved in the
final aerosol foam formulation. DME rapidly
evaporates after spraying, and the amount was
reduced to 0.5% of the initial amount after
2 min. This led to the formation of a
supersaturated environment, where Cal and
BD crystals were absent for at least 26 h after
application. Cal/BD aerosol foam had
significantly greater in vitro skin penetration
and had increased bioavailability compared
with Cal/BD ointment. Both formulations
effectively occluded the skin.
Conclusion: A stable supersaturated solution of
Cal/BD in the aerosol foam leads to increased
bioavailability and explains the improved
clinical effect when compared to the Cal/BD
ointment.
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Psoriasis is a chronic, immune-mediated
inflammatory disorder characterized by scaly
plaques of thickened skin [1, 2]. Many patients
with psoriasis are treated topically with vitamin
D3 analogues and corticosteroids, either as
separate products used together or as a fixed
combination treatment [3]. The fixed
combination calcipotriene 0.005% (Cal) and
betamethasone dipropionate 0.064% (BD) in
ointment and gel formulations are established
as routine treatments for psoriasis [4].
Adherence to topical therapies is often poor
due to the inconvenient and cumbersome
nature of available therapies [5], but also due
to low efficacy of these therapies [6]. Hence,
adherence to the topical treatment could
potentially be enhanced by designing a topical
product with improved cosmetic properties,
easier application and improved efficacy.
Considerable research has been undertaken to
improve drug delivery as the effect of
medication depends on the bioavailability of
the active ingredients [7].
In response to patients’ needs, a novel
alcohol-free and surfactant-free aerosol foam
formulation of Cal/BD has been developed
[8–13]. The Cal/BD aerosol foam is a
pressurized formulation of a vehicle base with
Cal and BD dissolved in an innovative mixture
of volatile propellants, butane and dimethyl
ether (DME). When the formulation is sprayed
from the can, the propellants evaporate rapidly
and a thin layer of foam is formed on the skin.
Compared with the Cal/BD ointment, improved
skin blanching and clinical efficacy of the Cal/
BD aerosol foam have been confirmed in
previously reported studies [13, 14].
To be effective, topical treatments require
penetration of the active ingredient into the
skin; poor penetration can lead to low or lack of
clinical efficacy [7, 15, 16]. The ability for a
given active ingredient to penetrate the stratum
corneum (SC) depends on several factors
[16–19]:
– Condition of the skin barrier.
– Physicochemical properties of the active
ingredient.
– Partitioning of the active ingredients
between vehicle and skin.
– Concentration of active ingredient dissolved
into the vehicle and its subsequent
thermodynamic activity.
The condition of the skin barrier and the
physicochemical properties of the active
ingredient (e.g. shape, size, lipophilicity,
charge) are key factors to consider when
designing new topical therapies. The
physicochemical properties of the active
ingredients and vehicle influence the partition
of the active ingredients between vehicle and
skin. To enhance penetration of the active
ingredient, approaches such as addition of
chemical penetration enhancers have been
used [20, 21], however these can result in
drying of the skin, irritation or inflammatory
reactions [20, 22, 23].
The rate of skin penetration is proportional
to the concentration of dissolved active
ingredients in the vehicle as increased
thermodynamic activity drives the active
ingredients into the skin [16]. Several studies
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have shown increased skin penetration or
clinical effect of topical therapies with more
versus less dissolved active ingredient in a
vehicle [7, 24, 25]. Various ways of increasing
the ratio of dissolved:solid active ingredient in a
vehicle have been described previously
[16, 18, 26]. One method to dissolve more
active ingredient is to prepare a supersaturated
solution of the active ingredient in the vehicle,
thus increasing the concentration of dissolved
active ingredient and subsequently increasing
the thermodynamic activity of the drug.
However, for the system to be effective in a
clinical setting, the supersaturation should be
stable for clinically relevant time ranges, e.g.
24 h, and should not readily form crystals, as
crystallization will decrease penetration of the
active ingredient [16].
Occlusion, by plastic wraps, tape,
impermeable dressings or vehicles containing
fats or polymer oils, are well-known methods to
increase the effect of a topical therapy. The SC
effectively limits water evaporation from the
body [17, 27] and its permeability and
hydration depend on the activity of water on
the outer surface [28]. Thus, occlusion of the
skin will alter the SC hydration level and can
subsequently increase the permeability of drugs
[28, 29].
The Cal/BD aerosol foam and ointment
contain the same active ingredients and
pharmaceutical excipients, except for the
propellents of the aerosol foam. None of the
excipients are considered chemical penetration
enhancers, and the two formulations are used to
treat the same disease. Thus, the condition of
the skin, physicochemical properties of the
active ingredients and vehicles, and chemical
penetration enhancers will not be considered
further.
The objective of this study is to investigate
the factors influencing skin penetration of the
active ingredients in the two formulations;
specifically to assess whether the
stable supersaturated solution of the active
ingredients and/or occlusive properties of Cal/
BD aerosol foam account for the observed




Solubility curves for Cal and BD as a function of
percentage DME in the propellant composition
(w/w) were constructed. Solutions were
prepared by adding varying amounts of DME
and butane (totaling 47 mL) to compositions
containing 13 mg Cal (as monohydrate), 67 mg
BD and 20 g vehicle base (liquid paraffin, white
soft paraffin and PPG-11-stearyl ether). Samples
were shaken vigorously until the contents
appeared homogenous, after which they were
left overnight, resulting in sedimentation.
Samples for analysis were taken from the top
of the composition, placed in a water bath at
40 C for 5 h until the propellant had fully
evaporated, and subsequently cooled for 1 h at
room temperature. The amount of Cal and BD
present in each sample was determined using
high-performance liquid chromatography.
Evaporation Studies
The evaporation of DME and butane from the
sprayed dose of Cal/BD aerosol foam was
determined following passive evaporation.
Samples were obtained by spraying 0.20 g Cal/
BD aerosol foam (equivalent to 0.08 g foam
base) onto a piece of paper, which was then
spread to obtain an even surface. The samples
were then allowed to stand for passive
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evaporation, thereby mimicking the intended
clinical administration of the product. At
appropriate time points samples were
withdrawn for analysis. The experiment was
performed in triplicate at an ambient
temperature (20–25 C). For determination of
the initial amount of propellants in the sprayed
dose, additional samples were prepared: (i) by
capturing all Cal/BD aerosol foam base and
propellants expelled by spraying directly into
gas-tight vials; and (ii) by transferring the
sample into gas-tight vials after escape of
propellants not bound to the foam base in the
sprayed dose, obtained by spraying Cal/BD
aerosol foam onto a piece of paper and
allowing it to stand for 30 s.
The amount of propellants present in the
samples of Cal/BD aerosol foam was determined
quantitatively using a gas chromatography
headspace method with flame ionization
detection, which allowed for simultaneous
measurements of the two propellants.
Identification of Crystals and/or Crystal
Formation
The Cal/BD aerosol foam and ointment samples
were prepared for crystal identification by
placing a small amount of the product on an
objective glass and smearing it with a cover
glass to obtain a thin film. Cal/BD aerosol foam
was assessed as a function of time whereas Cal/
BD ointment, a static system, was assessed
immediately after application. For optical
microscopy, the sample was placed under a
Leica M205 stereomicroscope (Leica
Microsystems GmbH, Wetzlar, Germany)
equipped with circular polarizers and viewed
in transmitted light; pictures were taken at
2009 magnification.
For the Raman imaging, the sample was
placed under a Renishaw Invia Raman
microscope (Renishaw plc, Gloucestershire,
United Kingdom) and viewed in both reflected
and transmitted light. Reference spectra of Cal
monohydrate, Cal anhydrate, BD and two
placebo formulations (ointment and aerosol
foam) were acquired as single-point
measurements. Streamline imaging maps were
made on both sample types. For the aerosol
foam, the same area of the sample was then
scanned at different time points, creating a
series of maps that would demonstrate if solid
particles of BD or Cal had formed. The time
study continued for 26 h and the recorded
image size was up to 100 9 300 lm with a
spartial resolution of 2 9 2 lm or 3 9 3 lm.
X-ray powder diffraction (XRPD) patterns
were collected with a PANalytical Empyrian
diffractometer (Panalytical, Almelo, The
Netherlands). Cal/BD aerosol foam and
ointment diffraction patterns were measured
in the sample holder 7 days and 5 min after
application, respectively, and compared against
reference patterns for Cal monohydrate, Cal
anhydrate and BD. The XRPD patterns were
collected in the 2-theta range from 5 to 17,
with a stepsize of 0.013 and a counting time of
11,993 s. Furthermore, the sample was spun to
ensure better particle statistics.
In Vitro Penetration Analysis
Foam formulations with different ratios of
DME:butane were prepared (Table 1) by filling
aerosol containers with the vehicle base,
crimping the valves and adding the
propellants through the valves.
The concentrations of Cal and BD in the
foam compositions, pre-application (as a
solution in the can) and post-application (in
the sprayed foam), are shown in Table 2.
The in vitro penetration of Cal and BD was
studied as a function of percentage DME in the
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composition into and through intact pig ear
skin using the preparations above (Table 1).
PermeGear (PermeGear Inc, Hellertown, PA,
USA) diffusion cells (n = 6), with a recipient
phase consisting of 0.04 M isotonic phosphate
buffer (pH 7.4) and 4% bovine serum albumin,
were used. The formulations (6 mg/cm2) were
applied to the pig ear skin and samples were
collected after 21 h. Non-absorbed medication
was removed with a cotton swab, followed by
tape-stripping twice using Transpore (3M, St.
Paul, MN, USA) tape. The skin biopsy was
subsequently added to a digestion buffer of
proteinase K enzyme and placed in a water
bath for pulsatory sonication. A sample from
the resulting homogenate and from the
recipient fluid was precipitated with ethanol
and methanol, respectively, prior to analysis.
Concentrations of Cal and BD were assessed
using liquid chromatography-mass
spectrometry to determine distributions of the
active ingredients. A non-parametric analysis
of variance (Kruskal-Wallis) was used to
analyze the influence of % DME in the
composition on the amount of Cal and BD in
the skin and the recipient fluid. P values below
0.05 were considered to be statistically
significant.
Human Skin Explant Biomarker Study
Anonymized human skin samples from
abdominoplasty surgery were acquired from
Biopredic International, France (female donor,
53 years old) and from the Department of Plastic
Surgery, Herlev Hospital, Denmark (male donors,
29 and 53 years old) upon written informed
consent of the donors. For each donor, 16 lL of
Cal/BD aerosol foam (n = 6), ointment (n = 6) or
vehicle (n = 3) were applied to full-thickness skin
in a static PermeGear diffusion cell setup (total of
three donors). After 21 h, biopsies were taken to
assess the bioavailability of Cal and BD in the
living layers of the skin. The gene expression of
cytochrome P450 24A1 (CYP24A1), which is
induced upon target engagement of the
Table 1 Foam compositions with different ratios of DME:butane (A, B, C) and the ﬁnal ratio found in the Cal/BD aerosol
foam
Amount per container A B C Final Cal/BD
aerosol foam
Vehicle base, g 30 30 30 30
DME, mL 10 35 45 30
Butane, mL 60 35 25 40
% DME of composition (w/w) 9 32 40 27
BD betamethasone dipropionate 0.064%, Cal calcipotriene 0.005%, DME dimethyl ether
Table 2 Cal and BD concentrations in the pressurized container and sprayed foam after evaporation of propellants
Pre-application Post-application
Calcipotriene (as monohydrate) 20 lg/g (21.4 lg/g) 50 lg/g (52.2 lg/g)
Betamethasone (as dipropionate) 0.2 mg/g (0.264 mg/g) 0.5 mg/g (0.643 mg/g)
BD betamethasone dipropionate 0.064%, Cal calcipotriene 0.005%
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vitamin D receptor, was used to monitor the
bioavailability of Cal in the skin. The reference
genes PPIA, GAPDH and ACTB were used for
normalization. The percentage of B-17-P, a
metabolite of BD primarily formed in the viable
layers of the skin, was measured in relation to
total BD in the epidermis. A two-way ANOVA
test was used to analyze the influence of donor
and formulation on the amount of CYP24A1
mRNA and B-17-P in the skin.
Occlusion Studies
Beakers (50 mL) were filled with milliQ water
and covered with pig ear skin (separated from
the fat and cartilage) so skin was in contact with
the water. The skin samples were secured using
plastic strips and placed on a 35 C heating
plate at a room temperature of 23 C and
humidity of 33%. The skin was allowed to
equilibrate for 20 min before baseline
transepidermal water loss (TEWL)
measurements were taken (expressed as g/m2/
h). For each skin sample, 0.14 g of each
formulation was spread on an area of 7 cm2.
After 5 min, the TEWL values were measured
non-invasively by gently placing a vapometer
(Delfin, Kuopio, Finland) on the skin. The
measurements were comprised of mean values
from five skin samples, and each were measured
three times with the vapometer. The percentage
evaporation compared with untreated skin was




In order to obtain a formulation in which the
active ingredients are dissolved in the
propellants, the solubility of the active
ingredients in various compositions of DME
and butane was determined.
The solubility of Cal and BD appears to rise
with increasing concentrations of DME and
decreasing concentrations of butane (Fig. 1).
An estimated minimum of 6% and 11% of
DME in the composition (w/w) is required to
dissolve Cal and BD, respectively. The
percentage of DME in the final Cal/BD aerosol
Fig. 1 Solubility of a Cal and b BD as a function of %
DME in composition (w/w). The solubility of Cal (a) or
BD (b) does not increase beyond 18% or 27% DME,
respectively, as all added Cal or BD is dissolved; potentially
the solubility could be increased further at higher % DME
compositions. The dotted lines show the solubility of Cal
or BD in the ﬁnal Cal/BD aerosol foam (27% DME of
composition), and the dashed lines illustrates the strength
of Cal and BD in the aerosol foam (20 lg/g Cal and
0.264 mg/g BD, corresponding to 50 lg/g Cal and
0.5 mg/g betamethasone, respectively, in the sprayed
foam). BD betamethasone dipropionate, Cal calcipotriene,
DME dimethyl ether
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foam is 27% (Table 1). Thus, the BD and Cal
available in the Cal/BD aerosol foam are
completely dissolved at this ratio.
Evaporation Studies
To investigate the amount of solvent remaining
in the sprayed foam, an evaporation study was
conducted. Evaporation of DME and butane in
Cal/BD aerosol foam as a function of time is
depicted in Fig. 2. DME had a faster evaporation
rate than butane at room temperature (20 C;
vapor pressure 510 vs 220 kPa, respectively).
Within 30 s, the amount of DME was reduced to
\2% of the initial amount by passive
evaporation, corresponding to 4 mg/g foam
base. Within 2 min of application, the total
amount of DME and butane was reduced to
0.5% and 4% of the initial dose, respectively
(Fig. 2).
Identification of Crystals and/or Crystal
Formation
After the propellants have evaporated the active
ingredients can either remain in solution to
create a supersaturated solution, or crystallize.
The foam and ointment were analyzed to
identify crystals.
Microscopic images of Cal/BD ointment
showed both Cal (needle-shaped) and BD
(small corn-shaped) crystals immediately after
application. In contrast, crystals were not
observed in microscopic images of Cal/BD
aerosol foam up to 18 hours after application.
After 15 days crystals were observed (Fig. 3).
These observations were supported by Raman
imaging, where Cal and BD crystals were
identified in Cal/BD ointment but not in the
CaI/BD aerosol foam within the time frame of
26 h after application (Fig. 4). XRPD patterns of
Cal and BD as reference, and Cal/BD aerosol
foam and Cal/BD ointment patterns are shown
in Fig. 5. Patterns of Cal/BD foam and Cal/BD
ointment were captured 7 days after application
to the sample holder and BD diffraction
patterns were not detected in the Cal/BD
aerosol foam formulation; however, it was
identified in Cal/BD ointment. Cal crystals
were not detected as concentrations were
below the limit of detection.
In Vitro Penetration Analysis
Penetration of Compositions of Increasing
DME Concentrations
The percentage of BD penetrated into the skin is
significantly higher with formulation B
containing 32% (6.8 ± 1.8%) and formulation
C containing 40% (7.2 ± 2.3%) DME compared
with the Cal/BD ointment (2.5 ± 1.2%,
illustrated as 0% DME in Fig. 6). The
percentage of BD from formulation A
containing 9% of DME was not statistically
significantly different to all other formulations
investigated.
Similar results were observed for Cal in
in vitro skin penetration experiments: higher
Fig. 2 Evaporation of DME and butane over time. DME
had a faster evaporation rate than butane and within 2 min
the total amount of DME and butane had reduced to 0.5%
and 4% of the initial amount, respectively. DME dimethyl
ether
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Cal skin penetration occurred as % DME in the
formulation increased from 0 (Cal/BD
ointment) to 32% DME (formulation B; data
on file, LEO Pharma A/S).
Penetration of the Final Cal/BD Aerosol
Formulation Compared with the Ointment
A concentration of 27% DME in the
composition was chosen for the final Cal/BD
aerosol foam formulation.
Administration of the final Cal/BD aerosol
foam formulation led to significantly higher
levels of Cal (P\0.001) and BD (P = 0.002) in
pig ear skin compared with ointment (Table 3).
The levels of Cal and BD that permeated
through the skin into the recipient phase were
generally very low or below the level of
detection, with the exception of Cal at 21 h
(aerosol foam, 34 ± 13%; ointment 15 ± 12%;
P = 0.026 between products).
Fig. 3 Microscopic imaging. a Microscopic images of Cal/
BD ointment, where both Cal (needle-shaped) and BD
(small corn-shaped) crystals are observed when the
formulation is applied. b Microscopic images of Cal/BD
aerosol foam over time. No Cal or BD crystals were
observed up to 18 hours after application. After 15 days
crystals were observed. BD betamethasone dipropionate,
Cal calcipotriene
Fig. 4 Raman imaging. Left Overlay Raman image map
identifying a needle-shaped Cal crystal and a small
corn-shaped BD crystal in the Cal/BD ointment at
application. Pixel size: 3 9 3 lm. Right Overlay Raman
image map of Cal/BD aerosol foam at 26 h after
application; no cal or BD crystals could be identiﬁed.
Pixel size: 2 9 2 lm. Cal is shown in green, BD in red and
vehicle in blue. BD betamethasone dipropionate, Cal
calcipotriene
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Human Skin Explant Biomarker Study
Treatment for 24 h with Cal/BD ointment and
Cal/BD aerosol foam strongly induced the gene
expression of CYP24A1 compared with the
vehicle control (Fig. 7a). Treatment with Cal/
BD aerosol foam resulted in higher expression
levels of CYP24A1 than Cal/BD ointment
(Fig. 7a). Similarly, the relative amounts of
B-17-P after application of Cal/BD aerosol
foam were higher than after application of
Cal/BD ointment (Fig. 7b). In summary, the
bioavailability of both Cal and BD in the living
layers of the skin was higher after Cal/BD
aerosol foam application compared with Cal/
BD ointment, although this effect was not
statistically significant using a total of three
donors.
Occlusion Studies
The TEWL measurements from pig ear skin
through the Cal/BD aerosol foam and Cal/BD
ointment compared with untreated skin is
shown in Fig. 8. The Cal/BD ointment tends to
be more occlusive than the Cal/BD aerosol
foam, although this was not statistically
significant. Both formulations were shown to
have extensive occlusive properties.
DISCUSSION
Clinical studies have shown Cal/BD aerosol
foam to be more efficacious than Cal/BD
ointment in patients with psoriasis vulgaris
[9, 13]. In this study we have investigated the
factors influencing skin penetration of the
active ingredients in the two formulations.
Supersaturated cutaneous formulations
using DME as the volatile solvent have not
been investigated before. DME and butane,
commonly used as propellants in hair sprays,
deodorants and other consumer products, are
liquids when under high pressure and gases
when exposed to atmospheric pressure. In the
pressurized aerosol foam formulation, DME
serves as a solvent for the vehicle base as well
as the active ingredients, Cal and BD. The
solubility studies showed that the amount of
DME in the Cal/BD aerosol foam ensures the
Fig. 5 Comparison of the XRPD patterns of Cal (mono-
hydrate and anhydrate) and BD with the pattern of Cal/
BD ointment and aerosol foam, 7 days after application.
BD crystals were observed in the ointment, while no
crystals were observed in the aerosol foam, even after
7 days. The amount of Cal crystals in suspension were
below the limit of detection. BD betamethasone dipropi-
onate, Cal calcipotriene, XRPD X-ray powder diffraction
Fig. 6 Penetration of BD into skin or receptor medium as
a function of percentage DME of composition (w/w;
mean ± SD). Penetration of BD from the Cal/BD
ointment is indicated by 0% DME and open symbols.
BD betamethasone dipropionate, Cal calcipotriene, DME
dimethyl ether
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active ingredients are fully dissolved inside the
container. The change in concentration of
dissolved Cal and BD from a pressurized liquid
state in the can to a foam state on the skin, is
illustrated in Fig. 9.
As the aerosol foam is sprayed from the can
and the formulation is no longer under
pressure, DME and butane undergo phase
transition and evaporate as gas. We found
that a very limited amount of DME and butane
remained in the foam 2 min after application.
The rapid evaporation allows the dissolved Cal
and BD to be distributed in the sprayed foam
on the skin as a supersaturated solution.
Supersaturated solutions can often be
unstable and crystallize readily [20, 30];
however, the lack of crystallization of Cal and
BD in the sprayed foam observed in this study
Fig. 7 Bioavailability of Cal and BD in the skin
a CYP24A1 mRNA, and b % B-17-P of total BD-related
material in human skin samples (mean ± SD; n= 3
donors). BD betamethasone dipropionate, Cal calcipotriene
Fig. 8 Evaporation of water from skin following no
treatment, Cal/BD aerosol foam or Cal/BD ointment
(mean ± SD). BD betamethasone dipropionate, Cal cal-
cipotriene, SD standard deviation
Table 3 Quantities of Cal and BD found in skin and recipient ﬂuid 21 h after topical application to pig ear skin
(mean ± SD, n = 6)
Formulation Active substance Skin, % of applied Recipient ﬂuid,
% of applied
Cal/BD ointment Cal 6 ± 3 15 ± 12
BD 2.6 ± 1.2 NA
Cal/BD aerosol foam Cal 30 ± 9 34 ± 13
BD 6.2 ± 4.0 NA
NA samples below lower limit of quantiﬁcation, BD betamethasone dipropionate 0.064%, Cal calcipotriene 0.005%, SD
standard deviation
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illustrates the formation of a supersaturated
environment that is stable during clinical use.
It is evident from our data that a greater
amount of Cal and BD from the supersaturated
solution of Cal/BD foam diffuses into the skin
compared with Cal/BD ointment. We also
showed that the degree of skin penetration
depends on the amount of the active
ingredients dissolved in the propellant
mixture, as shown by increasing the % DME of
composition. When fully dissolved (Cal/BD
aerosol foam), the penetration of active
ingredients exceeds that in which the active
ingredients are partly suspended (Cal/BD
ointment).
In addition, we investigated the
bioavailability of Cal and BD in human skin,
which supported an increased penetration of
Cal/BD aerosol foam into the skin compared
with Cal/BD ointment. Both the ointment and
the sprayed foam were found to be occlusive.
Although this finding supports the clinical
efficacy of both fixed combination Cal/BD
products, alone it does not explain why Cal/
BD aerosol foam is more effective than
ointment.
CONCLUSION
In conclusion this study shows that a
stable supersaturated solution of the active
ingredients is formed when the solvent for the
active ingredients evaporates rapidly after
application. This phenomenon leads to greater
skin penetration of the active ingredients and
thereby an increased bioavailability explaining
the superior efficacy of Cal/BD aerosol foam
compared to the ointment.
Fig. 9 Change in concentration of active ingredients dissolved in the aerosol foam formulation over application time. BD
betamethasone dipropionate, Cal calcipotriene
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